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ABSTRACT 
 
Madhu, Malav. M.S., Department of Pharmacology and Toxicology, Wright State University, 
2009. Impact of Diabetes on ACE/ACE2 Balance and Angiotensin II Type 1 Receptor Expression 
in db/db Diabetic Mice. 
 
 
Alterations in the renin-angiotensin system (RAS) are considered to be crucial for 
the development of diabetic complications like hypertension and nephropathy. Our 
previous work demonstrated role of AT1 receptors (AT1R) in the development of 
hypertension in db/db diabetic mice. The aim of this study was to test the hypothesis that 
there is upregulation of renal AT1R and imbalance in renal ACE/ACE2 homeostasis in 
db/db mice. In addition, we hypothesize that treatment with an anti-hyperglycemic or an 
AT1R blocker will correct this imbalance. Five week old control and db/db mice were 
housed in metabolic cages for 24 hour collection of urine. At early age of 5 weeks, db/db 
mice were obese and hyperglycemic. Urinary albumin excretion was also significantly 
high in db/db mice. Changes in RAS were evaluated using enzyme activities, western 
blots and immunohistochemistry. There was a significant increase in urinary ACE2 
activity and ACE2 content in db/db mice at 5 weeks. There was a significant increase in 
plasma ACE activity and Ang II content in db/db mice compared to controls at 8 weeks. 
Western blot analysis showed significant increase in AT1R protein expression in 8, 18 
and 31 week db/db mice compared to controls. There was upregulation of ACE2 and 
down-regulation of ACE in kidney to compensate the effects of high plasma Ang II. To 
study the effect of reduction in blood glucose and AT1R blockade, mice were treated 
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with metformin and losartan for 12 weeks. Chronic treatment with metformin (150 
mg/kg/day) and losartan (10 mg/kg/day) significantly decreased urinary albumin and 
protein excretion. Metformin improved blood glucose and glucose tolerance db/db mice, 
but did not affect renal expression of ACE, ACE2 and AT1R. Although chronic losartan 
treatment did not alter blood glucose levels, it improved the morphology of pancreatic 
islets. There was a significant increase in renal AT1R protein expression and decrease in 
renal ACE2 protein expression following losartan treatment. Losartan treatment 
significantly increased urinary ACE2 activity. Western blot of concentrated urine from 8 
week db/db mice revealed immunoreactive bands of ACE, ACE2 and AT1R protein. 
Conclusion: 1) There is upregulation in renal AT1R protein expression in db/db mice. 2) 
Chronic metformin treatment significantly reduces blood glucose and microalbuminuria 
in db/db mice without affecting ACE/ACE2 balance. 3) Chronic losartan treatment had 
no effect on blood glucose, but it up-regulates renal AT1R and down-regulates renal 
ACE2. 4) Enzyme activity and western blot shows increased excretion of ACE2 in the 
urine of db/db mice. These data show that urinary ACE and ACE2 provide good index of 
intra-renal RAS status and could be used in early diagnosis and prognosis of diabetic 
renal disease.      
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INTRODUCTION 
Diabetes 
Diabetes mellitus is a chronic metabolic disorder resulting in hyperglycemia and 
disturbances of carbohydrate, fat, and protein metabolism. Diabetes is occurring at an 
epidemic rate in the United States and other western countries (Mokdad et al., 2001). In 
the year 2000, there were approximately 171 million people with diabetes worldwide; 
estimates for 2030 suggest that the prevalence of diabetes will increase to 366 million 
(Wild et al., 2004). According to Centers for Disease Control and Prevention, the risk of 
death among individuals with diabetes is almost twice that of individuals who do not 
have diabetes of similar age (USNDFS, 2005). For individuals born in 2000, the risk for 
developing diabetes is 33% for males and 39% for females. Diabetes is a huge burden on 
our healthcare system (USNDFS, 2005). The total estimated cost of diabetes in 2007 was 
174 billion in US only (Ettaro et al., 2004). One in 5 healthcare dollars in the US is spent 
caring for someone with diagnosed diabetes (Ettaro et al., 2004). The exact cause of 
diabetes is still unknown and many factors like obesity, genetics, diet, environment, 
individual lifestyle are believed to play part in the pathogenesis. There are 3 types of 
diabetes: 1) Type 1 diabetes mellitus caused by beta-cell destruction that leads to absolute 
insulin deficiency, hyperglycemia and ketosis, 2) Type 2 diabetes mellitus characterized 
by insulin resistance and relative insulin deficiency and 3) Gestational diabetes which 
occurs in 5-10% pregnant women with no previous history of diabetes. Of all diabetics, 
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90 to 95% have type 2 diabetes.  Kidney disease, heart disease, blindness, nervous system 
disease, dental diseases are some of the complications of diabetes. 
Diabetes, hypertension and kidney disease 
Diabetic nephropathy (DN) is a leading cause of end-stage renal disease (ESRD) that 
requires renal dialysis or kidney transplantation (USRDS, 2003). When kidney disease is 
caught late, ESRD usually follows. Nearly 44% of all new patients enrolled in ESRD 
treatment programs have diabetic background (USRDS, 2003). The number of people in 
the United States with ESRD has doubled between 1991 and 2001. In the year 2000, 
expenditures for about 400,000 patients with ESRD in the United States totaled about $20 
billion, meaning that the cost to manage ESRD for each patient in the year 2000 was 
$50,000 (Rodby, 2004). According to United States Renal Data System, diabetes mellitus 
is the single largest cause of ESRD requiring chronic dialysis or kidney transplantation in 
the US.  
 Hyperglycemia may lead to nephropathy by a number of mechanisms (Larkins & 
Dunlop, 1992). Sustained hyperglycemia of diabetes causes microvascular dysfunction, 
which contributes to the development of ESRD (Futrakul et al., 2006;Jawa et al., 2006). 
Many transmembrane proteins translocate glucose into the cells (Brosius & Heilig, 2005). 
Intracellular glucose and its metabolites give rise to vasoactive peptides and elevate 
intraglomerular pressure (Wautier & Schmidt, 2004). Advanced glycation end-products 
mediate renal tissue injury by producing reactive oxygen species (ROS) (Cooper, 2004) 
and by initiating signaling events through activation of protein kinase C, mitogen 
activated protein kinase and nuclear factor-κ of activated B cells. This would be followed 
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by over activity of tumor growth factor-β and thereby alter expression of extracellular 
matrix proteins (Jakus & Rietbrock, 2004).  ROS can then cause apoptosis of podocytes, 
thus initiating kidney damage (Susztak et al., 2006). Moreover, acute elevations in 
glomerular filtration rate (GFR) were observed in patients in response to glucose infusion 
(Christiansen et al., 1981). 
Circulating leptin levels are increased in patients with obesity and type 2 diabetes 
(Nyholm et al., 1997). High serum leptin levels cause an increase in sympathetic tone 
which then leads to hypertension and other related complications (Considine et al., 
1996;Haynes, 2005). It has also been reported that hypertensive individuals have high 
leptin levels and are at high risk of developing diabetes (Adamczak et al., 2000). 
Hypertension is twice as common in type 2 diabetics and is responsible for many 
complications of diabetes (Sowers et al., 2001). Kidney plays an important role in the 
development of hypertension. In fact, kidney disease is both a cause and a consequence 
of hypertension (Paul et al., 2006). One study reports that normotensive rats receiving a 
kidney from genetically hypertensive donor rats develop hypertension (Navar, 2005). On 
the contrary, genetically hypertensive rats who have had bilateral nephrectomy and 
receive a kidney from normotensive rats exhibit a reduction in blood pressure (Navar, 
2005). Increase in renal vascular resistance, induced by hyperglycemia, can lead to 
diminished GFR. Many patients at risk of hypertension manifest reduced renal blood 
flow and elevated filtration fraction even before development of hypertension (Navar, 
2005).  
The first sign of renal damage in diabetes is the presence of persistent microalbuminuria 
(24-hour urinary albumin excretion of 30 to 300 mg/day), hypertrophy of epithelial cells 
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and thickening of glomerular basement membrane (Cooper, 1998). This stage is known 
as incipient nephropathy. 20% to 40% of patients show this symptom 10 to 15 years after 
the onset of diabetes (Lee, 2005). Unfortunately, the onset of type 2 diabetes is often 
difficult to ascertain and so when a patient presents for the first time with type 2 diabetes, 
they may already have microalbuminuria. In type 2 diabetes, the microalbuminuria is 
seldom reversible and is probably a sign of endothelial dysfunction (Ritz, 2003). 
Progression to proteinuria (urinary albumin excretion >300 mg/day) occurs in patients 15 
to 20 years following the onset of diabetes and this stage is known as overt nephropathy 
(Lee, 2005). Following this, the creatinine clearance start to decline at an average rate of 
10 to 12 mL/min/year in untreated patients and hypertension develops (Parving et al., 
2001).  
Optimization of glycemic control helps to reduce onset of DN (Hasslacher et al., 1989). 
In this study, we want to study the effect of metformin, a glucose sensitizer, on renal 
outcomes of DN. A variety of anti-hypertensive therapies produce beneficial effects in 
reducing proteinuria (Cooper & Johnston, 2000). However not all antihypertensive agents 
are the same in terms of delaying the progression of renal disease in diabetic patients. The 
renin-angiotensin system plays an important role in the pathogenesis of kidney disease. A 
substantial amount of evidence demonstrates that blockade of the renin-angiotensin 
system provides renoprotection (Hostetter, 2003;Lewis et al., 1993;Maschio et al., 1996). 
Renin-angiotensin system (RAS) 
The renin-angiotensin system (RAS) has been implicated in the pathophysiology of the 
diabetic renal disease (Andersen et al., 2000;Lewis, 2002). The functional roles of RAS 
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in the regulation of blood flow, sodium, bicarbonate and water transport, cell growth and 
differentiation have also been clarified. There is evidence of presence of RAS in pancreas 
of  human (Tahmasebi et al., 1999), mouse (Leung et al., 1998) and dog (Chappell et al., 
1992). RAS plays a key role in renal injury (Taal & Brenner, 2000;Hollenberg & Raij, 
1993). It is one of the major targets in the treatment of DN (Ye et al., 2004;Ye et al., 
2006;Tikellis et al., 2003). Drugs that interrupt RAS cascade are widely used in the 
management of diabetes and its complications. Additionally, weight gain and obesity are 
believed to activate RAS in humans (Barton et al., 2003). 
The RAS has long been recognized to play a crucial role in the regulation of blood 
pressure and electrolyte balance (see diagram 1). Angiotensinogen (AGT) is converted to 
to angiotensin I (Ang I) by the enzyme renin secreted by kidney. Ang I has little or no 
biological activity. Ang I is further catabolized by ACE to the biologically active peptide 
angiotensin II (Ang II) (Skeggs, Jr. et al., 1956). Ang II is found in circulation, in tissues 
and even in cells making it an endocrine, paracrine and intracrine peptide (Kumar et al., 
2007). Ang II has been shown to cause vasoconstriction, renal tubule sodium re-
absorption, growth promotion, cellular dedifferentiation, increased aldosterone secretion, 
polydipsia and increased sympathetic outflow (Giacchetti et al., 2005). Ang II directly 
contributes to the progression of chronic kidney disease, including DN (Lewis et al., 
1993;Maschio et al., 1999;Parving et al., 2001). In renal interstitial fluid, the 
concentration of Ang II is 1000 times higher than plasma (Seikaly et al., 1990). That is 
why kidney is a very important organ when studying hypertension and diabetes. 
Recently, an ACE-related carboxypeptidase (ACE2) was identified and cloned 
(Donoghue et al., 2000). ACE2 primarily cleaves Ang II into angiotensin 1-7 (Ang 1-7) 
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and less preferably degrades Ang I to angiotensin 1-9 (Ang 1-9) (Donoghue et al., 
2000;Li et al., 2005;Eriksson et al., 2002). Interestingly, these products of ACE2 
cleavage appear to have effects that oppose those of ANG II (Haulica et al., 2003). Thus, 
the vasoconstrictor/proliferative or vasodilator/anti-proliferative actions of RAS are 
primarily driven by ACE-ACE2 balance. 
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Renin-Angiotensin System Enzyme Cascade 
 
 
Santos R. A. S. et.al. Exp Physiol 2008 
 
Abbreviations: AMP, aminopeptidase; AT1, Ang II type 1 receptor; AT2, Ang II type 2 
receptor; Mas, Ang(1–7) receptor Mas; D-Amp, dipeptidyl-aminopeptidase; IRAP, 
insulin-regulated aminopeptidase; PCP, prolyl-carboxypeptidase; PEP, prolyl-
endopeptidase; NEP, neutral endopeptidase and (P)RR, Renin/prorenin receptor. 
 
Diagram 1: A schematic representation of the renin-angiotensin system cascade 
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Angiotensin converting enzyme (ACE) 
 ACE was discovered in plasma in 1956 by Leonard T. Skeggs (Skeggs, Jr. et al., 1956). 
ACE is a monomeric, membrane bound, zinc and chloride dependent di-peptidyl 
carboxypeptidase (Riordan, 2003). ACE was also found to be present in other organs 
such as kidney, heart, pancreas and brain (Nash, 1992). ACE plays a crucial role in RAS; 
it catalyzes the cleavage of decapeptide Ang I to produce a potent vasoconstrictor Ang II, 
by removal of carboxy terminal peptides. ACE also less preferably hydrolyzes the 
inactive Ang (1-9) to produce vasodilator Ang (1-7) (Tschope et al., 2002). Ang II is a 
potent vasoconstrictor and mediates its effects through AT1 and AT2 receptors (Higuchi 
et al., 2007). Pathological activation of tissue ACE with resulting increase in local Ang II 
produces deleterious effects on kidney and heart during organ remodeling (Dzau et al., 
2002). ACE promotes degradation of bradykinin, which acts as a vasodilator via 
stimulation of nitric oxide (Carey & Siragy, 2003). The kidney, under the regulation of 
Ang II and aldosterone, maintains the electrolyte balance in the body. A recent study on 
ACE expression revealed that higher ACE was associated with an increased diabetic 
pathologies like renal dysfunction and high blood pressure (Ye et al., 2004;Senador et al., 
2009). High ACE leads to high production of Ang II followed by increased blood 
pressure and subsequent kidney damage due to hyperfiltration. Inhibition of ACE has 
been shown to decrease systemic blood pressure, albuminuria and glomerular capillary 
pressure (Mathiesen et al., 1991;Ahmad et al., 1997;Lewis et al., 1993). Aside from 
lowering blood pressure, ACE inhibitors have found to improve the prognosis of patients 
with congestive heart failure and myocardial infarction (Garg & Yusuf, 1995). 
 
8 
 
Angiotensin converting enzyme 2 (ACE2) 
ACE2, a new homologue of ACE, was identified and cloned by two separate groups in 
the year 2000 (Donoghue et al., 2000;Tipnis et al., 2000). ACE2 displays 42% sequence 
homology and 62% sequence similarity with NH2-terminal catalytic domain of ACE and, 
like ACE, is a type 1 integral membrane protein (Tipnis et al., 2000). ACE2 is not 
inhibited by the ACE inhibitors captopril and lisinopril (Tipnis et al., 2000). Unlike ACE, 
ACE2 levels in plasma are very low and this could be due to less shedding of ACE2 from 
plasma membrane of endothelial cells (Rice et al., 2006). Our previous study shows that 
ACE2 activity is not detectable in the plasma of diabetic and control mice (Elased et al., 
2006). ACE2 was first found to be present in kidneys, heart and testes but later studies 
show its widespread distribution (Donoghue et al., 2000;Tipnis et al., 2000;Hamming et 
al., 2004). In kidneys, ACE2 is particularly found in apical membranes of the proximal 
tubules and in podocytes (Soler et al., 2008). ACE2 is a carboxy-peptidase that primarily 
cleaves vasoconstricting Ang II to vasodilator Ang (1-7).  Ang (1-7) acts on Mas, a G-
protein coupled receptor, to exert its vasodilatory action (Pinheiro et al., 2004) and  thus 
ACE2 acts in a counter-regulatory manner with ACE, keeping production and actions of 
Ang II in ckeck. Furthermore, ACE2 activity has been detected in urine of healthy 
subjects (Warner et al., 2005) and sheep (Shaltout et al., 2007). Studies have shown that 
ACE2 protein expression and activity changes in diabetic kidneys (Wysocki et al., 
2006;Ye et al., 2006). It has been shown that Ang II can upregulate ACE and down 
regulate ACE2 (Koka et al., 2008). Administration of MLN-4760, a specific ACE2 
inhibitor, worsens albuminuria in db/db mice together with increased glomerular 
expression of fibronectin (Ye et al., 2006). Moreover, ACE2 null mice develop a 
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progressive, age-dependent cardio-myopathy with increased oxidative stress, collagenase 
levels and hypertrophy together with increased urinary albumin excretion (Oudit et al., 
2007). Whereas, generation of double mutant ACE-ACE2 null mice prevented cardiac 
dysfunction suggesting cardio-protective role of ACE2 (Crackower et al., 2002). Another 
study reports that ACE2 null mice do not develop cardiac complications but they show 
high plasma Ang II levels and increased pressor sensitivity after Ang II infusion (Gurley 
et al., 2004). Thus, ACE2 counteracts pressor activity of Ang II by its degradation and by 
production of Ang (1-7) having depressor activity. 
Angiotensin II type 1 receptor (AT1R) 
One of the aims of the present study is to investigate the effect of losartan, an AT1R 
blocker (ARB), on kidney function and intra-renal RAS in db/db diabetic mice. The 
actions of Ang II are mediated by AT1 and AT2 receptors which, invariably mediate 
opposite functions (Carey & Padia, 2008).  Most of the effects of Ang II, such as 
hypertension, atherosclerosis and heart failure, are mediated by AT1R, a seven 
transmembrane G-protein coupled receptor (Higuchi et al., 2007). AT1Rs are expressed 
in kidney, heart, adrenal gland, brain, lung and adipose tissue (de et al., 2000). Studies 
indicate that AT1R signaling in endothelial cells induce endothelial dysfunction 
(Nakashima et al., 2006). Dysfunctional endothelium is characterized by less production 
of nitric oxide, accelerated vasoconstriction, smooth muscle proliferation and a 
prothrombotic state (Watanabe et al., 2005). Ang II has been shown to reduce baroreflex 
sensitivity by interacting with AT1R, contributing to the development of hypertension 
(Gao et al., 2005). By its action on AT1R, Ang II causes generation of oxidative radicals 
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and promotes inflammatory processes like atherosclerosis and vascular aging (Fyhrquist 
& Saijonmaa, 2008).  
A recent study reported that Ang II infusion causes decrease in plasma adiponectin, an 
insulin sensitizer via AT1R in rats (Ran et al., 2006). Suppression of adiponectin may be 
a mechanism whereby Ang II impairs glucose tolerance and explains why hypertensive 
patients are at more risk of developing diabetes. In fact, treatment with ARBs reduce new 
onset of diabetes by 15-30% (Aguilar & Solomon, 2006). Our previous study showed 
that, losartan treatment reduced blood pressure without affecting glucose handling in 
db/db mice (Senador et al., 2009). Blockade of AT1R reduces cardiovascular 
complications in animal models of type1 and type 2 diabetes (Nielsen et al., 
2003;Amazonas & Lopes De Faria, 2006).     
It has been reported that Ang II suppresses glucose induced insulin release from isolated 
islets and pre-treatment of islets with losartan restores the effect of glucose. This effect of 
Ang II is partly because of reduction in (pro)insulin biosynthesis (Lau et al., 2004). A 
recent study showed up regulation of AT1 receptor together with over expression Ang II 
content in cavernous tissue of type 1 diabetic rats suggesting its possible role in erectile 
dysfunction (Yang et al., 2009). In present study, we will investigate whether there is 
upregulation of renal AT1 receptor protein expression in db/db diabetic mice. 
Changes in RAS homeostasis in diabetes  
The balance between Ang II and Ang (1-7), reflecting ACE and ACE2 activities, 
respectively, is considered as physiologically significant ratio (Huentelman et al., 2004). 
Over activity of the RAS has been identified as an important determinant in the etiology 
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of diabetes, heart disease and therefore represents a major target for therapy. In young 
db/db diabetic mice, the pattern of ACE and ACE2 expression in the renal cortical 
tubules was characterized by decrease in ACE and an increase in ACE2 (Ye et al., 2004). 
In diabetic rat and human kidneys, ACE is redistributed towards glomeruli and away 
from proximal tubules (Anderson et al., 1993). Furthermore, glomerular immunostaining 
for ACE2 decreases and that of ACE increases in db/db mice at the age of 8 weeks (Ye et 
al., 2006). At this age, db/db mice excrete more albumin in urine without obvious signs 
of renal pathology (Sharma et al., 2003). Furthermore, increased ACE expression was 
related to ACE2 inhibition in diabetic mice, suggesting that the ACE2-Ang (1-7)-Mas 
axis may play a renoprotective role by negatively regulating the ACE-Ang II- AT1 axis 
(Soler et al., 2007). Kidney also sequesters Ang II from circulation via AT1R mediated 
mechanisms (Navar, 2005). Therefore, sustained increase in plasma Ang II, as seen in 
diabetes, results in more uptake of Ang II by kidneys.    
Diagnosis of diabetic nephropathy 
The biggest challenge for healthcare professionals is accurate and early detection of 
diabetic kidney disease. Considerable scientific effort has been dedicated to identify 
patients at risk for the development of diabetic nephropathy (Susztak & Bottinger, 2006). 
There are some hurdles in diagnosis of kidney disease. Standard method for the diagnosis 
of diabetic nephropathy is renal biopsy which is a painful process and can suffer from 
sampling errors (Sharma et al., 2005). Detection of albumin in urine is the only 
noninvasive technique available for the diagnosis of diabetic nephropathy. Unfortunately 
the onset of diabetes is difficult to ascertain and so many patients diagnosed with high 
blood glucose already have microalbuminuria (Lee, 2005). Microalbuminuria is seldom 
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reversible in type 2 diabetics (Ritz, 2003). The problem with albuminuria as a disease 
marker is twofold. Microalbuminuria is a poor predictor of diabetic nephropathy (Perkins 
et al., 2007); proteinuria (macroalbuminuria), which is a strong predictor, only develops 
at advanced stages of diabetic nephropathy, when little can be done to prevent the 
development of ESRD. Furthermore, the immunoassay to measure albuminuria can detect 
only immunoreactive forms of albumin where as immunounreactive forms are not 
detectable by this conventional method (Comper & Osicka, 2005). An undiagnosed and 
untreated microalbuminuria progresses to proteinuria and at this point little can be done 
to stop progression of nephropathy. An early diagnosis is necessary for early treatment 
and to prevent further kidney damage.  
A lot of research is going on to find a better biomarker for kidney disease. For instance, 
N-acetyl β-glucosaminidase is a lysosomal enzyme derived from proximal tubular cells 
which is not filtered by kidney under normal circumstances. Its excretion increases in 
circumstances that cause tubular injury (Basturk et al., 2006). Smad1 is a transcription 
factor for mesangial matrix expansion. Its excretion increases in early stage of diabetic 
nephropathy and decreases with olmesartan treatment (Mima et al., 2008). 
Angiotensinogen, which is also a part of RAS, is also a potential candidate (Kobori et al., 
2009). Urine testing for biomarkers could substitute renal biopsy as safe and painless 
alternative. 
Aggressive control of hyperglycemia and hypertension is very important in the 
management of diabetic nephropathy. Effectiveness of ACEIs and ARBs illustrate the 
contribution of RAS in development of diabetes and its complications. Nevertheless, the 
effect of these medications on renal and urinary RAS remains a matter of debate. To 
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clarify the issue, we studied the effect of an anti-diabetic, metformin and an anti-
hypertensive, losartan on renal RAS using db/db mice as a model of type 2 diabetes.  
 
 
              
 
 
 
 
 
 
 
 
 
 
HYPOTHESIS AND SPECIFIC AIMS 
Hypothesis: 
There is upregulation of AT1 receptor protein expression and imbalance in ACE/ACE2 
homeostasis in the kidney of db/db mice. Treatment with an anti-hyperglycemic or an 
AT1 receptor blocker will correct this imbalance.   
Specific aims: 
1. To test the hypothesis that there is upregulation of renal AT1 receptor protein 
expression in db/db mice. 
2. To test the hypothesis that early treatment with metformin or losartan will correct 
the imbalance of ACE and ACE2. 
3. To test the hypothesis that urinary ACE2 could be used as an early biomarker for 
diabetic nephropathy. 
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MATERIALS AND METHODS 
Animals: 
Five week old db/db mice of the strain BKS.cg-m +/+ Leprdb/J and their age matched 
non-diabetic littermates were used. Animals were purchased from The Jackson 
Laboratory (Bar harbor, ME). Mice were housed individually at 22° C with a 12:12-hour 
light-dark cycle (6:30-18:30, lights on). Mice were maintained on a standard pellet diet 
with tap water available ad libitum. Cages were examined daily to assess the health of the 
animals. The obese (db/db) mouse strain has a point mutation in diabetes (db) gene 
encoding the leptin receptor gene. At early age, they serve as a good model of type 2 
diabetes, characterized by hyperinsulinemia, obesity and progressive hyperglycemia. All 
experimental protocols were approved by WSU Animal Care and Use Committee. 
1. Chronic treatment with metformin and losartan 
Five to 8 week db/db and control mice were randomly assigned to metformin and losartan 
treatment groups. Each group consisted of 8 mice. Losartan group received 10 mg/kg/day 
losartan dissolved in drinking water for 12 weeks. Metformin group received 150 
mg/kg/day metformin in drinking water for 12 weeks. After 12 weeks of treatment, mice 
were euthanized by decapitation trunk blood was collected in ice-chilled heparin washed 
tubes. Plasma was immediately separated by centrifugation at 10,000 x g for 10 minutes 
at 4° C and stored at -80° C. Tissues were collected in dry ice and stored at -80° C. 
2. Western blot analysis  
Control and db/db mice were sacrificed by decapitation and kidneys were quickly 
removed and homogenized on ice in phosphate buffered saline (PBS) containing protease 
inhibitor (Complete lysis M, Roche diagnostics, Mannheim, Germany). Tissue 
homogenates were centrifuged at 10,000 x g for 10 mins at 4° C to remove cellular 
debris. Total protein content was determined in supernatant using BSA as a standard and 
BioRad reagent (BioRad, Hercules, CA). Fifty microliter of tissue lysate was added to 50 
µl sample loading buffer (8% SDS, 125 mmol/L Tris-HCl, pH-6.8, 20% glycerol, 0.02% 
bromophenol blue, 100 mmol/L dithiothreitol) and boiled for 10 minutes. Approximately 
50 µg protein was loaded to 8% or 10% SDS-PAGE gel and separated by electrophoresis. 
Proteins on gel were then transferred (with Bio-Rad transfer apparatus, Hercules, CA) to 
a 0.2 µm PVDF membrane (Millipore, MA). The membrane was blocked for 1 hour with 
10% non-fat milk made in 10 mM Tris buffered saline with Tween 20 (TBS-T) at room 
temperature (R.T.). For analysis of ACE, ACE2 and AT1, membranes were probed with 
respective antibodies (Santa Cruz, CA) made in 5% non-fat milk in TBS-T for 2 days at 
4° C. Dilution for ACE and ACE2 antibodies was 1:200 while for AT1R antibody it was 
1:500. The membranes were then washed with TBS-T buffer 3 times for 5 minutes at 
R.T. Then membranes were incubated with horse radish peroxidase (HRP) conjugated 
donkey anti-rabbit secondary antibody (Jackson Immunoresearch, PA) made in TBS-T 
buffer with 1:40,000 dilution for 1 hour at R.T. Blots were detected using SuperSignal 
chemiluminescent substrate (Pierce, Rockford, IL) and visualized in Fujifilm image 
analyzer (LAS-3000 Image Quant, Sunnyvale, CA). ACE, ACE2 and AT1 have 
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molecular weights 195 kDa, 90 kDa, and 43 kDa respectively. The relative amounts of 
proteins of interest were determined by normalizing to β-actin. 
3. Plasma renin activity 
Renin activity assays were performed using a kit purchased from DiaSorin (Stillwater, 
MN). Mice were sacrificed by decapitation and trunk blood was collected in ice chilled, 
heparin washed tubes as described above. Plasma samples stored at -80° C were thawed 
and 100 µl plasma was transferred to 0.5 mL uncoated tubes. One microliter of PMSF 
and 10 µl of maleate generation buffer were added to plasma samples and mixed well. 
Fifty microliter of this mixture was transferred to ice chilled tubes. One set of tubes was 
incubated at 37° C and the other set was incubated at 4° C for 18 hours. After incubation, 
50 µl of samples, standards, blank and controls were transferred to appropriately marked 
angiotensin I antibody coated tubes. Then 500 µl of tracer-buffer solution was added to 
each tube followed by gentle vortex and incubated for 3 hours at room temperature. All 
tubes except ones for total count were decanted after incubation. Each tube was then 
counted in gamma counter for 1 minute. Renin activity was expressed as ng/mL/hr of 
generated Ang I. 
4. Urine collection and concentration 
Mice were put in metabolic cages for 24 hour collection of urine with free access to food 
and water. A total of 15 µl of protease inhibitor (Roche Diagnostics, IN) was added to 
each sample during 24 hour collection. Urine samples were centrifuged at 1,000 x g for 5 
minutes at 4° C to remove debris. Urine was then aliqouted and stored at -80° C. For 
concentration, frozen urine samples were thawed and mixed with protease inhibitor 
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(Sigma-Aldrich, MO) in a dilution of 1:1000. Samples were then concentrated in 
ultrafiltration chambers with a semi-permeable membrane (Millipore, MA) at 4° C. 
Concentrated samples were mixed with protease inhibitor (Sigma-Aldrich, MO) in a 
dilution of 1:100. The sample concentrates were then aliquoted and stored at -80° C for 
later use. 
5. ACE activity 
ACE activity assays were performed using a kit purchased from Alpco Diagnostics 
(Salem, NH). Mice were sacrificed by decapitation. Plasma, kidneys and urine were 
collected and processed as described above. Kidney lysate (80-100 µg) or plasma 
samples (10 µl) were incubated with 100 µl HEPES buffer containing synthetic substrate, 
3H-hippuryl-glycyl-glycine, at 37° C for 1 hour. For evaluation of urinary ACE activity, 
50µl of urine samples were incubated with 100 µl of the 3H-hippuryl-glycyl-glycine at 
37° C for 1 hour. Incubation was followed by acidification with 50 µl 1N HCl to stop the 
reaction. Tritiated hippuric acid was separated from unreacted substrate by extraction 
with 1.5 mL scintillation cocktail and measured in beta counter (Packard 18TR Liquid 
Scintillation Analyzer). ACE activity was expressed as Units/µg protein or Units/Liter as 
previously described (Neels et al., 1982). One unit (U/L) of ACE activity is defined as 
the amount of enzyme required to release 1 µmol hippuric acid per minute per liter of 
sample at 37° C.   
6. ACE2 activity 
ACE2 activity was measured using fluorogenic substrate 7-Mca-APK(Dnp) which is 
specific for ACE2 as described before (Vickers et al., 2002;Guy et al., 2003) with some 
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modification. Fluorescence of Mca is quenched by Dnp group until cleavage by ACE2. 
After cleavage fluorescence was detected at Excitation: 328 nm and Emission: 393 nm 
(FusionR Packard plate reader).  ACE2 activity was measured in presence of 10 mM 
lisinopril, an ACE inhibitor, to prevent any interference from ACE. Four microliter (32-
40 µg) of kidney protein or 50 µl of urine samples were incubated with the substrate in a 
buffer (50 mM Tris, 5 mM ZnCl2, 150 mM NaCl, 10 µM lisinopril) at 37° C. The plate 
was read at 0, 1, 2, 3, 4 and 18 hours. The results were expressed as pmoles/hr/µg protein 
of cleaved substrate.  
7. Immunohistochemistry 
Immunohistochemistry refers to the process of localizing proteins in cells of a tissue 
section by using antibodies binding specifically to antigens in biological tissues. Mice 
were injected with ketamine/xylazine mixture (100:8 mg/kg). Mice were then perfused 
transcardially with ice cold PBS to flush out the blood and then with 4% 
paraformaldehyde (PFA) for 10 minutes. Tissues were collected and fixed in 4% PFA 
overnight at 4° C. Tissues were then sent to AML laboratories for microtomy and 
staining (Rosedale, MD). Paraffin sections (4 µm) were deparaffinized by washing the 
sections with xylene and subsequent hydration by 100%, 95% and 70% ethanol. Then 
sections were transferred to 10 mM citrate buffer (pH 8.5) for 10 minutes at 95° C. Then 
sections were incubated in 5% normal donkey serum (Vector, Burlingame, CA) in PBS 
containing 0.1% Triton-X 100, for 1 hour at R.T. Sections were then incubated with 
rabbit anti-AT1 primary antibody (Santa Cruz, CA) in a dilution of 1:100 at 4° C 
overnight. Following this, the sections were washed with PBS 3 times and incubated with 
donkey anti-rabbit secondary antibody conjugated with Cyanine 3 fluorescent dye 
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(Jackson immunoresearch, PA) for 60 minutes at R.T. Slides were then allowed to dry in 
air and mounted with Vectashield mounting medium (Vector, Burlingame, CA). The 
slides were then visualized in a fluorescence microscope (Optronics, Goleta, CA). 
8. Measurement of blood glucose levels  
For determination of glucose, blood samples were withdrawn from a cut made on tail 
vein and measured using an Accu-Check Advantage Blood Glucose Monitor (Roche 
Diagnostics, Indianapolis, IN). The measuring limit of this monitor was 600 mg/dL. For 
measurement of higher levels of blood glucose, a glucose assay kit was purchased from 
Sigma (St.Luis, MO). For this assay, 5 µl blood was diluted in 25 µl of PBS buffer and 
300 µl of water. Ten microliter of diluted blood was incubated with 100 µl of assay 
reagent for 30 minutes at 37° C. Glucose is oxidized to gluconic acid and hydrogen 
peroxide by glucose oxidase. Hydrogen peroxide reacts with o-dianisidine in the presence 
of peroxidase to form a colored product. The reaction was stopped by addition of 100 µl 
12N H2SO4. Oxidized o-dianisidine reacts with sulfuric acid to form a more stable 
colored product. The intensity of the pink color measured at 540 nm is proportional to the 
original glucose concentration. We nullify the red color of blood by measuring blank 
reading at 600 nm and dividing one third of individual sample reading from actual 540 
nm reading. 
9. Glucose tolerance test (GTT) 
To study glucose handling in mice, intra-peritoneal (i.p.) GTT was performed. Mice were 
fasted for 16 hours. Fasting blood glucose was measured after the end of fasting period. 
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Mice were then given i.p. injections of 1.5 mg/kg glucose in an aqueous solution. Blood 
glucose was measured at 30, 60, 90, 120 minutes after glucose injection as described.   
10. Urinary albumin assay  
To monitor kidney function, quantitative estimation of urinary albumin was performed 
using a kit purchased from Bethyl Laboratories (Montgomery, TX). Urine samples were 
collected and stored as described above. In a 96 well plate, the wells were coated with 
100 µl goat anti-mouse albumin antibody diluted 1:100 in carbonate-bicarbonate buffer 
overnight at 4° C. After incubation, the antibody solution was aspired from each well and 
washed with 150 µl TBS-T buffer 3 times. Then each well was incubated with 200 µl 
blocking buffer (Tris buffered saline with 1% BSA) for 30 minutes and washed 3 times 
with TBS-T buffer. One microliter urine samples were diluted with 1 mL of conjugate 
buffer. One hundred microliter of diluted urine samples were added to each well and 
incubated at R.T. for 1 hour. At the same time, 100 µl of standards were added to 
assigned wells followed by 1 hour incubation. Albumin present in samples and standards 
binds with the coated antibody. Wells were then washed 5 times with TBS-T buffer. Then 
100 µl HRP conjugated detection antibody diluted 1:35,000 in conjugate buffer was 
incubated for 1 hour at R.T. for detection of bound antigen. Wells were then washed 5 
times with TBS-T buffer. Equal volumes of TMB substrate A and substrate B (KPL, 
Gaithersburg, MD) were mixed and 100 µl of this substrate was added to each well. HRP 
cleaves the substrate to produce color. The intensity of the color produced is directly 
proportional to the amount of albumin present in the sample. Plate was finally read at 450 
nm in FusionR Packard plate reader.  
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11. Measurement of plasma and renal Ang II  
Mice were sacrificed by decapitation and trunk blood was collected in ice chilled heparin 
washed tubes and kidneys were collected in dry ice. Plasma and kidney samples were 
processed as described above. Plasma and kidney Ang II contents were measured using a 
kit purchased from Alpco (Salem, NH). This technique uses double-antibody 
radioimmunoassay to measure Ang II. Ang II is extracted from 50 µl of plasma or 450-
500 µg kidney samples treated with 1 µl EDTA using reverse phase extraction by special 
columns followed by vacuum evaporation of liquid to form a pellet. The pellet was 
reconstituted in 120 µl Tris buffer.  Hundred microliter of standards and samples were 
incubated with 20 µl primary antibody for 16 hours at 2-8° C. After incubation, 40 µl of 
tracer was added to each tube and incubated at 2-8° C for 6 hours. 125I present in the 
tracer competes with Ang II present in the sample and standards for the same antibody 
sites. After 6 hour incubation, solid phase secondary antibody (20 µl) was added to the 
mixture and incubated at 2-8° C for 30 minutes. The antibody bound fraction was 
separated from liquid by centrifugation and counted in gamma counter (Micromedic 
Systems, Seattle, WA). Ang II content was expressed as pg/mL. 
12. Urinary creatinine assay  
Urinary creatinine assays were performed using a kit purchased from Quidel (San Diego, 
CA). The excretion rate of creatinine in a normal individual is relatively constant. Thus, 
urinary creatinine levels are useful in detecting renal disease and estimating the extent of 
impairment of renal function.  The assay is based on modified Jaffe reaction where 
alkaline picrate forms a colored solution in presence of creatinine. Urine samples were 
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collected and processed as described above. Samples and standards were diluted 1:40 
with distilled water. Fifty microliters of diluted samples and standards were added to 96 
well plate followed by addition of 150 µl of color reagent (7 mL picric acid + 1 mL 1N 
NaOH). This mixture was incubated for 30 minutes at R.T. and plate was read at 490 nm 
(FusionR Packard plate reader). The intensity of the color produced is directly 
proportional to the amount of creatinine present in the sample. 
Statistical analysis 
Diabetic db/db and control mice were separated in three groups, metformin treated group 
(n=8), losartan treated group (n=8) and untreated group (n=19). Students unpaired two 
tailed t test were performed to calculate p values. For multiple comparisons between two 
or more groups, one-way and two-way ANOVAs were carried out followed by Fisher’s 
LSD test. All data obtained are presented as mean ± SEM, and the criterion for statistical 
significance was set at p<0.05. Data were analyzed using Statistica software (v.7). 
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Figure 1: Weight (A) and water intake (B) of db/db mice and their age matched lean 
controls. *p<0.05, control vs. db/db. n=8-12 per group.  
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Mice 
 
Age 
 
Food intake 
(gms) 
Blood glucose 
(mg/dL) 
Control 5 week 
 
N.D. 145.25 ± 4.7 
 
db/db N.D. 230.38 ± 13.25* 
 
Control 8 week 
 
4.44 ± 0.05 158.8 ± 1.7 
 
db/db 8.92 ± 0.09* 568 ± 32.03* 
 
Control 10 
week 
3.77 ± 0.09 154.86 ± 7.18 
 
db/db 7.94 ± 0.14* 585.39 ± 12.36* 
 
 
Table 1: Time course of blood glucose and food intake in db/db mice and their age 
matched lean controls. *p<0.05, control vs. db/db, n=10 per group. N.D.: not determined 
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Mice Age Volume  (mL) Albumin 
(mg/day) 
Protein 
(mg/day) 
Creatinine 
(mg/mL) 
Control 5 week 0.7 ± 0.25 0.06 ± 0.02 
 
3.41 ± 1.22 0.42 ± 0.04 
db/db 2.7 ± 0.52 0.28 ± 0.05* 
 
3.6 ± 0.6 0.19 ± 0.03* 
Control 8 week 1.12 ± 0.21 0.09 ± 0.02 
 
4.57 ± 0.78 0.58 ± 0.03 
db/db 15.8 ± 2.2* 2.09 ± 0.38* 
 
16.34 ± 1.82* 0.09 ± 0.01* 
Control 14-15 
week 
0.61 ± 0.14 0.04 ± 0.01 
 
4.08 ± 0.85 0.52 ± 0.02 
db/db 25 ± 1.83* 8.02 ± 1.09* 
 
19.46 ± 3.55* 0.06 ± 0.01* 
Control 26 week 0.55 ± 0.07 0.02 ± 0.00 
 
N.D. 0.56 ± 0.02 
db/db 30.13 ± 1.23* 4.98 ± 0.91* 
 
N.D. 0.07 ± 0.00* 
Control 30 week 1.46 ± 0.27 0.05 ± 0.01 
 
7.61 ± 1.33 0.48 ± 0.02 
db/db 25.29 ± 3.81*† 2.86 ± 0.94*† 
 
22.12 ± 4.68*† 0.09 ± 0.01*† 
 
Table 2: Time course of urine volume, albumin, protein and creatinine excretion in 
control and db/db mice. Two-way ANOVA shows main effect of strain on volume [F(1,64) 
= 488.3, p<0.0001], albumin [F(1,63) = 140.34, p<0.0001], protein [F(1,54) = 39.84, 
p<0.0001] and creatinine [F(1,65) = 870.52, p<0.0001] excretion. There was a main effect 
of age on volume [F(4,64) = 27.67, p<0.0001], albumin [F(4,63) = 19.75, p<0.0001], protein 
[F(4,54) = 10.4, p<0.0001] and creatinine [F(4,65) = 2.94, p<0. 05] excretion. There is an 
interaction between strain and age for volume [F(4,64) = 27.68, p<0.0001], albumin [F(4,63) 
= 20.08, p<0.0001], protein [F(4,54) = 4.43, p<0.01] and creatinine [F(4,65) = 19.75, 
p<0.0001]. *p<0.01, control vs. db/db. †p<0.01, 30 week vs. 5 week. n=5-7 per group. 
N.D.: not determined.  
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Figure 2: Plasma ACE activity in 8 week (A) and 31 week (B) db/db mice and their age 
matched lean controls. *p<0.01, control vs. db/db. n=8 per group.  
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Figure 3: Plasma renin activity in 8 week (A) and 31 week (B) db/db mice and their age 
matched lean controls. *p<0.05, control vs. db/db. n=8 per group.  
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Figure 4: Renal ACE activity in 8 week (A) and 31 week (B) db/db mice and their age 
matched lean controls. *p<0.05, control vs. db/db. n=7-8 per group.  
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Figure 5: Renal ACE2 activity in 8 week (A) and 31 week (B) db/db mice and their age 
matched lean controls. *p<0.05, control vs. db/db. n=8 per group.  
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Figure 6: Urinary ACE2 activity in 5 week (A) and 30 week (B) db/db mice and their 
age matched lean controls. *p<0.05, control vs. db/db. n=6 per group.  
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Figure 7: Urinary ACE2 concentration in 5 week db/db mice and their age matched lean 
controls. *p<0.05, control vs. db/db. n=6 per group.  
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Figure 8: Renal AT1R protein expression in 8 week (A) and 31 week (B) db/db mice and 
their age matched lean controls. *p<0.05, control vs. db/db. n=8 per group.  
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Figure 9: Renal ACE protein expression in 8 week (A) and 31 week (B) db/db mice and 
their age matched lean controls. *p<0.05, control vs. db/db. n=9 per group.  
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Figure 10: Renal ACE2 protein expression in 8 week (A) 31 week (B) db/db mice and 
their age matched lean controls. *p<0.05, control vs. db/db. n=8 per group.  
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Figure 11: Plasma Ang II content in 8 week (A) and 31 week (B) db/db mice and their 
age matched lean controls. *p<0.01, control vs. db/db. n=8 per group.  
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Figure 12: Renal Ang II content in 8 week (A) and 31 week (B) db/db mice and their age 
matched lean controls. n=8 per group.  
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Figure 13: Effect of metformin on blood glucose of control (A) and db/db (B) mice. 
*p<0.05 untreated vs. metformin. n=6-8 per group.  
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Figure 14: Effect of losartan on blood glucose of control (A) and db/db (B) mice. n=6-8 
per group. 
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Figure 15: Glucose tolerance test in control mice after 9 weeks of metformin or losartan 
treatment. One-way ANOVA showed no main effect of treatment on area under curve. 
n=8 per group.  
42 
 
 
 
Figure 16: Glucose tolerance test in db/db mice after 9 weeks of metformin treatment. 
*p<0.0.5, untreated vs. metformin. n=8 per group.       
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Figure 17: Glucose tolerance test in db/db mice after 9 weeks of losartan treatment. n=8 
per group.  
 
44 
 
 
 
Figure 18: Urinary albumin excretion in 8 week (A) and 14 week (B) db/db mice and 
their age matched lean controls. Two-way ANOVA showed a main effect of strain at 8 
weeks [F(1,39) = 129.78, p<0.0001] and at 14 weeks [F(1,37) = 113.93, p<0.0001]. There 
was also a main effect of treatment at 14 weeks [F(2,37) = 6.57, p<0.01] but not at 8 
weeks. ANOVA also showed an interaction between strain and treatment at 14 weeks 
[F(2,37) = 6.56, p<0.01] but not at 8 weeks. * p<0.0001, control vs. db/db. #p<0.001, 
untreated vs. treated db/db mice. n=6-8 per group.  
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Figure 19: Urinary protein excretion in 8 week (A) and 14 week (B) db/db mice and their 
age matched lean controls. Two-way ANOVA showed a main effect of strain at 8 weeks 
[F(1,33) = 74.24, p<0.0001] and at 14 weeks [F(1,38) = 38.53, p<0.0001]. There was also a 
main effect of treatment at 8 weeks [F(2,33) = 17.86, p<0.0001] and at 14 weeks [F(2,38) = 
12.5, p<0.0001]. ANOVA also showed an interaction between strain and treatment at 8 
weeks [F(2,33) = 8.82, p<0.01] and at 14 weeks [F(2,38) = 12.52, p<0.001]. *p<0.01, control 
vs. db/db. #p<0.0001, untreated vs. treated db/db mice. n=5-8 per group.  
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Figure 20: Urinary creatinine excretion in 8 week (A) and 14 week (B) db/db mice and 
their age matched lean controls. Two-way ANOVA showed main effect of strain at 8 
weeks [F(1,43) = 228.22, p<0.0001] and at 14 weeks [F(1,43) = 401.29, p<0.01]. However, 
there was no main effect of treatments at 8 weeks and 14 weeks. ANOVA did not show a 
significant interaction between strain and treatment. *p<0.0001, control vs. db/db. n=7-8 
per group.  
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Figure 21: Renal ACE activity (A) and ACE2 activity (B) of 18 week db/db mice and 
their age matched lean controls. Two-way ANOVA showed main effect of strain for ACE 
activity [F(1,25) = 268.54, p<0.0001] and for ACE2 activity [F(1,27) = 33.18, p<0.0001]. 
However, there was no main effect of treatment on either ACE activity or ACE2 activity. 
There was no significant interaction between strain and treatment. *p<0.001, control vs. 
db/db. n=4-6 per group. 
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Figure 22: Urinary ACE activity in 14 week db/db mice and their age matched lean 
controls. Two-way ANOVA shows main effect of strain [F(1,30) = 71.72, p<0.0001] but 
not that of treatment. There was no significant interaction between strain and treatment. 
*p<0.01, control vs. db/db. #p<0.05 untreated vs. treated db/db mice. n=6-7 per group.  
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Figure 23: Urinary ACE2 activity in 8 week (A) and 14 week (B) db/db mice and their 
age matched lean controls. Two-way ANOVA showed main effect of strain at 8 weeks 
[F(1,34) = 80.19, p<0.0001] and at 14 weeks [F(1,39) = 117.89, p<0.0001]. There was a 
main effect of treatment at 8 weeks [F(2,34) = 9.3, p<0.001] and at 14 weeks [F(2,39) = 8.8, 
p<0.001]. There was an interaction between strain and treatment at 8 weeks [F(2,34) = 
8.58, p<0.01] and at 14 weeks [F(2,39) = 8.56, p<0.001]. *p<0.001, control vs. db/db. 
#p<0.01, untreated vs. treated. n=5-7 per group.  
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Figure 24: Effect of losartan on renal AT1R expression in 18 week control (A) and db/db 
(B) mice and their age matched lean controls. *p<0.05, untreated vs. treated. n=8 per 
group.  
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Figure 25: Effect of losartan on renal ACE expression in 18 week control (A) and db/db 
(B) mice and their age matched lean controls. n=8 per group. 
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Figure 26: Effect of losartan on renal ACE2 expression in 18 week control (A) and db/db 
(B) mice and their age matched lean controls. *p<0.05, untreated vs. treated. n=8 per 
group.  
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Figure 27: Effect treatments on morphology of pancreatic islets. Representative 
trichrome staining in control mouse (A), control mouse treated with losartan (B), control 
mouse treated with metformin (C), db/db mouse (D), db/db mouse treated with losartan 
(E), db/db mouse treated with metformin (F). Metformin and losartan treatments reduce 
collagen and preserves integrity of β-cells.  
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                  Control                                            db/db 
 
Figure 28: Immunohistochemical staining for AT1R in renal tissue sections from 8 week 
old mice. Kidney sections were stained as described in materials and methods.  
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Figure 29: Urinary expression of ACE, ACE2, AT1 and β-actin in 8 week db/db mice. 
Five week old db/db mice were treated with metformin (150 mg/kg/day) and losartan (10 
mg/kg/day) in drinking water.   
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RESULTS 
1. Anthropometric and metabolic parameters: 
To evaluate the progression of diabetes, body weight, water intake, food intake and blood 
glucose of control and db/db mice were measured. 
1.1 Body weight: Young 5 week db/db mice were obese and had significantly greater 
body weight compared to control mice. Diabetic db/db mice showed consistently higher 
body weights compared to controls throughout the 12 week study period (Figure 1A, 
p<0.05).  
1.2 Water intake: At 5 weeks, water intake was comparable between the two groups 
(control 6.15 ± 0.76 vs. db/db 7.3 ± 0.54, n=6). Starting from 6 weeks, water 
consumption of db/db mice increased significantly. With age db/db mice showed 
consistently higher water intake compared to control mice (p<0.05). 
1.3 Food intake: At 8 weeks, food intake of db/db mice was significantly higher 
compared to control mice (Table 1, p<0.05). High food intake of db/db mice was also 
noticeable at 10 weeks (Table 1, p<0.05).  
1.4 Blood glucose: At 5 weeks, blood glucose of db/db mice was significantly high 
compared to controls. There was a consistent increase in the blood glucose of db/db mice 
(Table 1, p<0.05). However, blood glucose of control mice remained rather constant. 
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2. Measurement of renal function: 
Renal function was evaluated by measurement of urinary albumin, protein and creatinine. 
Mice were placed in metabolic cages for 24-hour collection of urine. 
2.1 Urinary albumin: Albuminuria is a risk marker for diabetic nephropathy. At 5 weeks, 
there was a significant difference in urinary albumin excretion between control and db/db 
mice (Table 2, p<0.01). With age, kidney function worsens and albumin excretion 
increases further. At the age of 30 weeks, db/db mice excreted almost 10 times more 
albumin compared to 5 week old mice (Table 2, p<0.01). 
2.2 Urinary total protein: Urinary protein was measured by using Bradford’s reagent. At 
5 weeks, urinary protein excretion of db/db mice was not different compared with non-
diabetic controls (Table 2). Protein excretion of db/db mice increased significantly with 
age. By the age of 30 weeks, urinary protein excretion from db/db mice increased 6 fold 
compared to that of 5 week mice (Table 2, p<0.01).  
2.3 Urinary creatinine: Urinary creatinine levels are useful in estimating the extent of 
impairment of kidney function. In 5 week db/db mice, urinary creatinine concentration 
was significantly less compared to controls (Table 2, p<0.01). With the progression of 
diabetes, urinary creatinine concentration declined further. At 30 weeks also, urinary 
creatinine concentration of db/db mice was significantly less compared to control mice 
(Table 2, p<0.01). 
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3. Measurement of enzyme activities:  
3.1 Plasma ACE and renin activity: 
3.1.1 Plasma ACE activity: Plasma ACE activity was measured using 10 µl 
plasma samples. At 8 weeks, db/db mice had significant increase in plasma ACE 
activity compared to controls (Figure 2, p<0.01). The increase in plasma ACE 
activity was also observed in 31 week db/db mice (Figure 2, p<0.01). 
3.1.2 Plasma renin activity: Renin activity was measured in 100 µl plasma 
samples. There was no significant difference in renin activities between db/db and 
control mice at 8 weeks and at 31 weeks (Figure 3). 
3.2 Renal ACE and ACE2 activity: 
3.2.1 Renal ACE activity: Renal ACE activity was measured using 10 µl (80-100 
µg) kidney lysate. At 8 weeks, db/db mice had significant decrease in ACE 
activity compared to controls (Figure 4A, p<0.05). ACE activity in 31 week db/db 
mice was also significantly reduced compared to controls (Figure 4B, p<0.05). 
3.2.2 Renal ACE2 activity: Renal ACE2 activity was measured in 4 µl (32-40 µg) 
kidney lysate. Renal ACE2 activity was significantly increased in the kidneys of 
young 8 week db/db mice (Figure 5A, p<0.05). Higher ACE2 activity was also 
observed in 31 week old db/db mice (Figure 5B, p<0.05). 
3.3 Urinary ACE and ACE2 activity 
In this project, we propose to use urinary ACE and ACE2 as an index of intra-renal RAS 
status. 
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3.3.1 Urinary ACE activity: Urinary ACE activity was determined using ACE 
REA kit and 50 µl urine. Urinary ACE activity in young 5 week db/db mice was 
below the detectable limit (data not shown).   
3.3.2 Urinary ACE2 activity: Urinary ACE2 activity was determined using 
fluorogenic substrate Mca-APK (Dnp) in 50 µl urine in presence of ACE inhibitor 
(lisinopril). Five week mice had a significant increase in urinary ACE2 activity 
compared to controls (Figure 6A, p<0.05). Urinary ACE2 activity increased 4-
fold in db/db mice by the age 31 weeks (Figure 6B, p<0.05). 
3.3.3 Urinary ACE2 content: Urinary ACE2 content was measured by ELISA in 
50 µl urine. At 5 weeks, ACE2 content was increased significantly in db/db mice 
compared to control mice (Figure 7, p<0.05).   
4. Renal protein expression of ACE, ACE2 and AT1R: 
To study the effect of diabetes on renal protein expression of ACE, ACE2 and AT1R 
western blots were performed.  
4.1 AT1R expression: Renal AT1R expression was significantly high in 8 week db/db 
mice (Figure 8A, p<0.05). Higher expression of renal AT1R was also observed in 31 
week db/db mice (Figure 8B, p<0.05). These renal changes may explain hypertension 
associated with diabetes. 
4.2 ACE expression: In young 8 week db/db mice, kidney ACE expression was 
significantly less compared to their lean controls (Figure 9A, p<0.05). Old 31 week mice 
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also had lower kidney ACE expression when compared to control mice (Figure 9B, 
p<0.01) 
4.3 ACE2 expression: Young 8 week db/db mice exhibited significantly high renal ACE2 
expression than controls (Figure 10A, p<0.05). With progression of diabetes, kidney 
function declines and so does ACE2 expression. In kidneys of old 31 week mice, ACE2 
expression does not differ between control and db/db mice (Figure 10B). 
5. Plasma and kidney Ang II content: 
5.1 Plasma Ang II: Ang II content was evaluated in 45 µl of plasma containing 1 µl 
EDTA. At 8 weeks, plasma Ang II content of db/db mice was increased compared with 
control mice (Figure 11A, p<0.01). Plasma Ang II levels in old 31 week db/db mice were 
also significantly high compared to controls (Figure 11B, p<0.01). This finding is 
supported by high plasma ACE activity in db/db mice. 
5.2 Kidney Ang II: Ang II content was evaluated using 50 µl (450-500 µg) of kidney 
lysate. There was no significant difference in renal Ang II content between control and 
db/db mice at the age of 8 weeks and 31 weeks (Figure 12). This finding is supported by 
the fact that renal ACE expression and activity are reduced in db/db mice. Upregulation 
of ACE2 in kidney degrades excess Ang II, thereby keeping its deleterious effects in 
control. 
6. Effect of metformin: 
To study the effect of reduction in glycemia on renal and urinary outcomes, 5-8 week 
mice were treated with metformin (150 mg/kg/day) in drinking water for 12 weeks.  
61 
 
6.1 Effect of metformin on blood glucose: Metformin treatment in 8 week mice did not 
alter blood glucose levels (data not shown). We believe that the treatment was initiated 
after a significant rise in blood glucose of 8 week db/db mice. Therefore, another group 
of 5 week old db/db and control mice were treated with metformin for 12 weeks. 
Metformin treatment significantly reduced blood glucose of db/db mice during ad libitum 
feeding (Figure 13B, p<0.05). However, the treatment did not alter blood glucose of 
control mice (Fig 13A). To evaluate the effect of metformin on glucose handling, we 
performed i.p. glucose tolerance test. As expected, metformin treatment significantly 
improved glucose tolerance in db/db mice (Figure 16, p<0.05) but not in control mice 
(Figure 15).  
6.2 Effect of metformin on renal function: 
6.2.1 Albumin excretion: Three weeks of metformin treatment (150 mg/kg/day) 
did not alter urinary albumin excretion in db/db mice (Figure 18A). However, 9 
weeks of metformin treatment significantly reduced urinary albumin excretion 
(Figure 18B, p<0.001). The albumin excretion of control mice did not change 
during the treatment period. 
6.2.2 Total protein excretion: Treatment with metformin significantly decreased 
urinary total protein excretion in db/db mice (Figure 19, p<0.0001). However, 
there was no effect of the treatment on urinary total protein excretion of control 
mice (Figure 19). 
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6.2.3 Creatinine excretion: Metformin did not change creatinine concentration in 
urine of either db/db or control mice after 3 and 9 weeks of treatment (Figure 
20A).  
6.3 Effect of metformin on renal ACE and ACE2 activities: Chronic metformin treatment 
has no effect on renal ACE and ACE2 activities in either db/db or control mice (Figure 
21). 
6.4 Effect of metformin on urinary ACE and ACE2 activities: Metformin treatment has no 
effect on urinary ACE activity (Figure 22) or urinary ACE2 (Figure 23) activity in either 
db/db or control mice. 
6.5. Effect of metformin on renal expression of ACE, ACE2 and AT1: Metformin 
treatment has no effect on the renal expression of ACE, ACE2 and AT1R in db/db and 
control mice (data not shown). 
6.6 Effect of metformin on morphology of pancreatic islets: Pancreas sections from 18 
week mice were stained with Masson’s trichrome to study the effect of metformin 
treatment on islet morphology. Untreated db/db mice show disarray of cellular 
architecture and loss of their structural integrity. Chronic metformin treatment improved 
islet integrity. It also reduced fibrosis by reducing collagen around islets (Figure 27). 
7. Effect of losartan 
To study the effect of AT1R blockade on renal and urinary outcomes 5 week mice were 
treated with losartan (10 mg/kg/day) in drinking water for 12 weeks. 
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7.1 Effect of losartan on blood glucose: Chronic losartan treatment did not alter blood 
glucose in control (Figure 14A) and db/db mice (Figure 14B). To evaluate the effect of 
losartan on glucose handling, we performed i.p. glucose tolerance test. Losartan treatment 
had no effect on glucose tolerance of control and db/db mice (Figure 15).  
7.2 Effect losartan on renal function: 
Urine samples were collected after 3 and 9 weeks of initiation of the treatments. 
7.2.1 Albumin excretion: Three weeks of losartan treatment did not alter urinary 
albumin excretion in db/db mice (Figure 18A). However, 9 weeks of losartan 
treatment significantly reduced urinary albumin excretion (Figure 18B, p<0.001). 
There was no effect of the treatment on urinary albumin excretion of control mice.    
7.2.2 Total protein excretion: Treatment with losartan decreased urinary total 
protein excretion of db/db mice (Figure 19, p<0.0001). However, there was no 
effect of the treatment on urinary total protein excretion of control mice.  
7.2.3 Creatinine excretion: Losartan did not change creatinine concentration in 
urine of either db/db or control mice (Figure 20A).  
7.3 Effect of losartan on renal ACE and ACE2 activities: Losartan treatment did not 
affect renal ACE and ACE2 activity after 12 weeks of treatment (Figure 21). 
7.4 Effect of losartan on urinary ACE and ACE2 activities: Losartan increased urinary 
ACE2 activity in db/db mice (Figure 23, p<0.01). However, losartan had no effect on 
urinary ACE2 activity of control mice. Losartan has no effect on urinary ACE activity 
(Figure 22). 
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7.5 Effect of losartan on renal expression of ACE, ACE2 and AT1R: Chronic treatment 
with losartan significantly increased AT1 receptor protein expression in both db/db and 
control mice (Figure 24, p<0.05). However, the treatment decreased ACE2 protein 
expression (Figure 26, p<0.05) in both db/db and control mice. Losartan treatment had no 
effect on renal ACE expression (Figure 25). 
7.6 Effect of losartan on morphology of pancreatic islets: Untreated db/db mice show 
disarray of cellular architecture and loss of their structural integrity. Chronic losartan 
treatment improved islet integrity. It also reduced fibrosis by reducing collagen around 
islets (Figure 27). 
8. Immunohistochemistry of kidney: 
To confirm the results obtained from western blot analysis, immunohistochemistry was 
performed. As expected, AT1R expression was increased significantly in kidney tubules 
of db/db mice compared to controls (Figure 28). 
9. Western blots of concentrated urine: 
Urinary excretion of ACE, ACE2 and AT1R protein was studied using western blots. A 
total of 80 µg of concentrated urinary protein was added in each lane. Immunoblot of 
ACE revealed two immunoreactive bands at 190 kDa and ~70 kDa. The smaller band 
may be a degradation fragment of intact 190 kDa ACE. Immunoblot of ACE2 revealed 
only one band at ~70 kDa which represents degradation fragment of integral ACE2. 
Single immunoreactive bands of AT1R and β-actin were also detected at 43 kDa and 42 
kDa respectively (Figure 29). The bands of β-actin were not consistent for each sample 
so as to be used as a control protein. 
DISCUSSION 
This study tested the hypothesis that there is upregulation of AT1 receptors and 
imbalance in ACE/ACE2 homeostasis in the kidneys of db/db mice. In addition we 
studied the effects of chronic metformin and losartan treatment on renal RAS. Metformin 
is widely prescribed as a blood glucose lowering drug for type 2 diabetics. It is an insulin 
sensitizer which is thought to act by reducing hepatic glucose output and enhancing 
peripheral glucose uptake (Stumvoll et al., 1995;Cusi et al., 1996). Initially a group of 8 
week old db/db and control mice were treated with 150 mg/kg/day metformin in drinking 
water. The treatment did not affect blood glucose of either db/db or control mice. Eight 
week db/db mice had very high average blood glucose (more than 500 mg/dL) at the start 
of the treatment. Therefore, we think that metformin was ineffective in reducing blood 
glucose. To achieve glycemic control, young 5 week db/db and control mice were treated 
with metformin (150 mg/kg/day) for 12 weeks. On this occasion metformin treatment 
improved both glycemia and glucose tolerance in db/db mice. The time of initiation of 
metformin treatment is critical for lowering blood glucose. 
In present study, losartan treatment had no effect on blood glucose and glucose tolerance 
of db/db and control mice. Some studies indicate that AT1 receptor blockers improve β-
cell function and glucose tolerance and delay the onset of type 2 diabetes in humans 
(Lindholm et al., 2002) and in mouse (Chu et al., 2006). Some epidemiological data 
indicates that RAS blockade delays the onset of type 2 diabetes in patients with 
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hypertension (Yusuf et al., 2005). ARBs and ACEIs are thought to affect glucose 
metabolism by improving insulin sensitivity (Moan et al., 1996;Fogari et al., 1998). 
However, our previous study shows that chronic losartan treatment reduces blood 
pressure in db/db mice without affecting glucose tolerance (Senador et al., 2009). One 
reason for improved glucose tolerance by AT1R blockade could be timing of initiation of 
treatment. Our finding agrees with previous studies on db/db mice who initiated the 
treatment after glucose had started to rise (Mathew et al., 2005;Shao et al., 2006;Sugaru 
et al., 2007). Moreover, studies on streptozotocin induced diabetes and ob/ob mice 
reported failure of chronic losartan treatment to improve blood glucose (Raimondi et al., 
2004;Erbe et al., 2006). 
Although losartan treatment does not improve glucose tolerance, it improves morphology 
of pancreatic islets in db/db mice. RAS components like ACE, angiotensinogen and 
AT1R are reported be present in pancreatic islets (Lau et al., 2004). Activation of AT1R 
is believed to inhibit insulin release in response to glucose loading (Carlsson et al., 1998). 
Ang II also activates NAD(P)H oxidase and thus causes oxidative stress induced β-cell 
dysfunction and apoptosis (Nakayama et al., 2005). Treatment of db/db mice with 
candesartan improves granulation and reduces fibrosis and loss of endothelial cells in 
islets (Shao et al., 2006). In present study, losartan treatment improves islet morphology 
and integrity of β-cells. It should be noted that losartan treatment may increase insulin 
release but may not improve insulin resistance. Therefore, it may not alter glucose levels 
significantly. 
The first sign of nephropathy in diabetics is presence of persistent albuminuria. In db/db 
mice, significant  microalbuminuria develops as early as 8 weeks (Sharma et al., 2003). 
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In this study, microalbuminuria was evident at the age of 5 weeks in db/db mice. At the 
same time total protein excretion was not different between control and db/db mice. At 
this age db/db mice were hyperglycemic. Moreover, blood pressure in db/db mice starts 
to rise after the age of 11 weeks (Senador et al., 2009). Therefore in initial stages of 
kidney damage is triggered by high blood glucose levels. Hyperglycemia and RAS 
contribute in the development of nephropathy (Larkins & Dunlop, 1992;Andersen et al., 
2000). As mice become old, kidney function declines, measured by glomerular filtration 
rate (Sharma et al., 2003). At the age of 31 weeks, albumin excretion of db/db mice 
increases 10 fold compared to 5 week mice. Hyperinsulinemia has been found to increase 
transcapillary escape of albumin in non-diabetic subjects, providing a link between 
albuminuria and insulin resistance (Niskanen & Laakso, 1993). There are conflicting 
reports in the literature on the effect of metformin on albuminuria. One study reports 
reduction in urinary albumin excretion after metformin treatment in patients with type 2 
diabetes (Amador-Licona et al., 2000) while others did not find any difference between 
the treated and untreated groups (Imano et al., 1998;UKPDS,1998). The fact that 
metformin reduces both fasting (Fujita et al., 2005) and non-fasting (Fruehwald-Schultes 
et al., 2002) serum insulin levels, explains why it is effective in reducing albuminuria. On 
the contrary, the effectiveness of losartan in reducing albuminuria in normotensive 
(Zandbergen et al., 2003) and hypertensive (Brenner et al., 2001;Lozano et al., 
2001;Andersen et al., 2002) diabetic patients is well-known. Losartan blocks AT1R and 
attenuates many of the deleterious actions of Ang II in kidneys such as contraction of 
mesangial cells and glomerular arterioles (Manley, 2000), increase in membrane pore 
radius (Remuzzi et al., 1993), glomerular sclerosis and modulation of extra-cellular 
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matrix (Leehey et al., 2000). In present study, metformin and losartan significantly 
reduced urinary total protein excretion after 3 weeks of treatment. However, reduction in 
urinary albumin excretion was only noticeable after 9 weeks. The duration of treatments 
and time-points for urine collections were selected to compare our results with the 
literature (Hu et al., 2009;Chu et al., 2006).  
Western blot analysis of kidney shows that there is increase in ACE2 expression and 
decrease in ACE expression in young db/db mice. This combination attenuates Ang II 
accumulation and produces more Ang (1-7) in kidneys. Ang II over-activity is believed to 
play an important role in the pathogenesis of DN (Parving et al., 2001). Ang (1-7), 
produced by ACE2, is a vasodilator and anti-proliferative peptide that opposes the action 
of Ang II (Koitka et al., 2008). Interestingly, ACE2 expression decreases and ACE 
expression increases in the glomerulus of db/db mice, leading to altered glomerular 
permeability and albuminuria (Ye et al., 2006). Ang II can increase intraglomerular 
pressure by constricting both afferent and efferent arteriole, thereby stimulating urinary 
albumin excretion (Remuzzi & Bertani, 1998). It has also been revealed that in animals 
with experimental diabetes, intragmolerular pressure is increased even before systemic 
blood pressure rises (Hostetter et al., 1982). Therefore, kidney upregulates ACE2 to 
counteract pro-hypertensive processes and maintain its function. As they become old, 
ACE2 expression goes down and kidney function deteriorates. 
 One of the key findings in the present study is upregulation of AT1R in kidneys of db/db 
mice. AT1Rs are up regulated by conditions that increase Ang II like dehydration in rats 
(Barth & Gerstberger, 1999;Sanvitto et al., 1997) and sodium deficiency in mouse (Chen 
et al., 2003). These findings indicate that expression of AT1 receptors is affected by its 
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agonist Ang II. In a recent study, researchers found that systemic Ang II infusion 
increases AT1 receptor mRNA expression in brain tissue of rats (Wei et al., 2009). An 
increase in oxidative stress also leads to an increase in renal AT1R protein and mRNA 
expression causing stimulation of sodium transporters and hypertension (Banday & 
Lokhandwala, 2008). High blood glucose levels can increase reactive oxygen species and 
eventually oxidative stress to upregulate AT1R. AT1R mRNA and protein levels are also 
increased in vascular smooth muscles of type 2 diabetic patients (Hodroj et al., 2007). 
Another study reported upregulation of AT1 receptor together with over expression of 
Ang II in cavernous tissue of type 1 diabetic rats suggesting its possible role in erectile 
dysfunction (Yang et al., 2009). High levels of circulating insulin, as seen type 2 
diabetics, can also upregulate AT1 receptors in vascular smooth muscles (Hodroj et al., 
2007;Nickenig et al., 1998). Additionally, AT1R mRNA expression also increases in 
pancreatic islets of db/db mice (Chu et al., 2006).  This study shows that db/db mice have 
high levels of circulating Ang II. Therefore, it is plausible that high expression of AT1 
receptors in response to high circulating Ang II could lead to diabetes related 
hypertension in db/db diabetic mice. 
Treatment with losartan increases Ang II levels in the plasma in Lewis rats (Ferrario et 
al., 2005). As a result, losartan also increases cardiac ACE2 activity promoting 
production of Ang (1-7) form Ang II. High plasma Ang II may also cause stimulation of 
AT2 receptors to exert its beneficial effects. There are conflicting reports on effect of 
ARBs on AT1R expression. Some report an increase in AT1R with ARB treatment 
(Wang et al., 1997;Hu et al., 2009) while others report down regulation (Wei et al., 
2009). Our data show that renal AT1R protein expression increases following chronic 
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losartan treatment in both db/db and control mice. As mentioned earlier db/db mice 
already have high levels of circulating Ang II and an increase in Ang II results in an 
increase in AT1R. Therefore, losartan treatment is likely to up regulate AT1R in kidney, 
where Ang II is sequestered from plasma and is also a primary site of its action. Many 
reports in the literature suggest that blockade of AT1R increases ACE2 (Soler et al., 
2009;Ferrario et al., 2005;Igase et al., 2005;Whaley-Connell et al., 2006). In contrast, 
study by Xia and others did not find any significant change in ACE2 expression after 
losartan treatment (Xia et al., 2009). In this study, losartan treatment significantly 
reduced renal ACE2 protein expression in db/db and control. A recent study shows down 
regulation of ACE2 mRNA in rat astrocytes after Ang II treatment (Gallagher et al., 
2006). Therefore, an increase in plasma Ang II levels by losartan may cause 
downregulation of ACE2.  Although AT1Rs are blocked by losartan, they can be 
constitutively active and may act as autoreceptors (Zou et al., 2004). In this case, AT1R 
no longer need Ang II to initiate signaling and may affect expression of ACE2. Another 
possible mechanism for ACE2 downregulation may be action of Ang II or its derivatives 
on angiotensin receptors. There was no change in expression of renal ACE protein after 
losartan treatment. This finding agrees with study by Gallagher and others (Gallagher et 
al., 2006). However, chronic metformin treatment did not affect RAS parameters in either 
db/db or control mice. 
To confirm the data obtained from western blot, renal ACE and ACE2 activities were 
determined. As expected, ACE2 activity was increased and ACE activity was decreased 
in kidneys of 8 week db/db mice. On the contrary, plasma ACE activity and Ang II 
content were higher in 8 week db/db mice compared to controls and at this age mice are 
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not hypertensive (Senador et al., 2009). This means that kidney keeps deleterious effects 
of Ang II in check by upregulating ACE2. As mice become old, kidneys cannot keep up 
and systemic hypertension develops (Figure 5 vs. Figure 21). A ratio of high ACE2 to 
low ACE favors less Ang II accumulation in tissues like kidney, helping to maintain their 
function. Studies in the literature suggest that losartan treatment increases ACE2 activity 
(Ferrario et al., 2005;Xia et al., 2009;Jessup et al., 2006). In this study, losartan treatment 
does not change ACE activity in either db/db or control mice. Chronic losartan treatment 
reduces expression of ACE2 protein in the kidney, but it doesn’t change ACE2 activity. 
One reason for this could be sequestration of plasma Ang II by the kidney. Reduction in 
ACE2 protein caused by losartan in the kidney is compensated by high ACE2 activity to 
cleave the harmful Ang II.  
It is reasonable to assume that up regulation of ACE2 in kidneys may be reflected in 
urine samples. A study by Wakahara et. al. has shown that ACE2  mRNA expression in 
human renal tissue marginally correlated with the degree of proteinuria (Wakahara et al., 
2007). A strong correlation between proteinuria and urinary expression of ACE and 
ACE2 has also been observed in humans (Wang et al., 2008). In this study, we measured 
urinary ACE2 activity and ACE2 content in young 5 week mice. At this age, db/db mice 
excreted more ACE2 in urine compared to controls. Additionally, ACE2 activity in the 
urine of db/db mice was also higher compared to controls. Kidney upregulates ACE2 
sensing the change glycemia which is detected by urine analysis. At 5 weeks, urinary 
albumin excretion was also high in db/db mice but urinary total protein excretion was not 
different between the two groups. Furthermore, our study shows presence of ACE, ACE2 
and AT1 proteins in the urine of 8 week old db/db mice. Urinary ACE and ACE2 enzyme 
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activities were also high in 8 week db/db mice. ACE and ACE2 are both type 1 integral 
membrane protein comprising a large extracellular catalytic domain. ACE has been 
shown to be proteolytically released from cell surface (Parkin et al., 2004). Catalytically 
active forms of ACE have also been found in urine (Hooper, 1991) and plasma (Senador 
et al., 2009). On the contrary, ACE2 activity is not detectable in plasma (Elased et al., 
2006). Therefore, it likely that source of urinary ACE2 is kidney and that of urinary ACE 
is plasma. This study shows presence of ACE2 in urine of young db/db mice, using both 
sensitive catalytic assay and immunoblotting. Urinary ACE2 levels reflect intra-renal 
RAS status and have potential for diagnosis and prognosis of diabetic renal disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
Cardiovascular and renal diseases are long term complications of diabetes and are leading 
cause of morbidity and mortality. There is evidence of activation of RAS in diabetic 
animals and humans. Our previous study showed effectiveness of AT1R blockade in 
reduction of blood pressure in db/db mice. Present study shows for the first time, that 
there is upregulation of AT1R protein expression in kidneys of db/db mice that may 
contribute in the development of diabetes related hypertension. We also show that, 
chronic losartan (10 mg/kg/day) treatment has no effect on blood glucose levels although 
it improves morphology of pancreatic islets. In addition, losartan treatment increased 
AT1R protein expression but decreased ACE2 protein expression in both db/db and 
control mice. Losartan treatment also reduces urinary albumin and protein excretion in 
db/db mice. 
To investigate the effect of blood glucose reduction, mice were treated with metformin 
(150 mg/kg/day). As expected, metformin treatment improved blood glucose and glucose 
tolerance in db/db mice. Our study shows effectiveness of metformin in reducing urinary 
albumin and protein excretion. However, chronic metformin treatment did not change 
renal expression or activity of ACE and ACE2.   
One of the aims of this study was to examine if ACE2 could be used as a predictor for 
early phase of diabetic nephropathy. We show that there is an increase in urinary ACE2 
activity and ACE2 content in young 5 week, db/db mice. Present study also shows 
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presence of ACE, ACE2 and AT1R proteins in concentrated urine samples of 8 week 
mice. Our previous studies show that there is no detectable ACE2 activity in plasma. 
Therefore, kidney is the primary source of urinary ACE2. These findings suggest that 
urinary ACE2 could be a potential non-invasive biomarker of diabetic nephropathy. 
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APPENDIX A 
Urinary, but Not Plasma Angiotensin-Converting Enzyme 2 (ACE2), Is Associated 
with Diabetic Nephropathy 
Malav N Madhu, Rendong Quan, Nathan M Weir, Wenfeng Zhang, Mariana Morris, 
Khalid M Elased 
Boonshoft School of Medicine, Wright State University, Dayton, OH 
 
Diabetic nephropathy (DN) is a leading cause of end-stage renal disease worldwide. 
Alteration in the renin angiotensin system (RAS) is widely believed to contribute to 
kidney injury in diabetes. Currently, detection of urinary albumin is the only non-invasive 
technique used for diagnosis of DN. However, microalbuminuria is a poor predictor for 
DN, while proteinuria is only detectable in late stage nephropathy. Recent studies 
suggested that ACE2 is renoprotective in 8 week old murine model of type II diabetes 
(db/db mice). The aim of this study was to test the hypothesis that urinary ACE2 is an 
early marker for intra-renal RAS status and nephropathy in db/db diabetic mice. 
Individual urine samples were collected from 5-8 week old male db/db diabetic and 
control mice over 24 hours. Renal and urinary ACE2 activities were determined using the 
conventional fluorogenic substrate, Mca-APK (Dnp) and also using SELDI-TOF mass 
spectrometry (MS). Urinary ACE2 content was evaluated by ELISA. Urinary albumin, 
creatinine and protein were measured as an index of kidney damage. Renal ACE and 
ACE2 expression were determined by western blot. At an early age (5-6 weeks) db/db 
mice developed moderate hyperglycemia, hyperinsulinemia and mild albuminuria 
(p<0.01). Five week old db/db mice showed a significant increase in urinary ACE2 
content (p<0.05) and activity (p<0.01) compared to controls. This finding was confirmed 
by SELDI-TOF MS. There was increase in renal ACE2 expression and activity of 8 week 
db/db mice (p<0.05) while renal ACE expression was decreased in db/db mice (p<0.01) 
compared to controls. Interestingly, plasma ACE activity was significantly higher in 
db/db mice compared to controls (p<0.01). There was no detectable ACE2 activity in 
plasma suggesting urinary ACE2 was derived from the kidney. In conclusion, urinary 
ACE2 warrants further investigation as a potential non-invasive marker for early diabetic 
nephropathy. 
Poster accepted in the 63rd High Blood Pressure Research Conference, Chicago 2009 
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APPENDIX B 
Upregulation of Angiotensin AT1 Receptors in Hypertensive db/db Diabetic Mice 
Malav N Madhu, Nathan M Weir, Rendong Quan, Denielle Senador, Wenfeng Zhang, 
Mariana Morris, Khalid M Elased 
Boonshoft School of Medicine, Wright State University, Dayton, OH 
 
Hypertension is a major cause of cardiovascular and renal disease in diabetics. In our 
previous studies we showed that high blood pressure in obese db/db diabetic mice can be 
reduced by angiotensin AT1 receptor (AT1R) blockade. The aim of this study was to 
assess the changes in renal and aortic AT1R expression and pressor response to chronic 
angiotensin II (Ang II) infusion in db/db mice. Western blot analysis was used to measure 
renal and aortic protein expression in 8-18 week old male db/db mice and their lean 
controls. AT1R expression was significantly increased in kidneys and aorta of db/db mice 
compared to controls (p<0.01). Immunohistochemistry showed increased 
immunostaining for AT1R in cortical kidney tubules and glomeruli of db/db mice 
compared to controls. There was also a significant increase in plasma ACE activity 
(p<0.01) and plasma Ang II (p<0.05) in db/db mice compared to controls. Another group 
of 8 week old db/db mice were implanted with carotid telemetric probes and 24 hr mean 
arterial pressure (MAP), heart rate (HR) and activity were monitored weekly. MAP began 
to increase in db/db mice after the age of 11 weeks during both light and dark periods 
when compared to controls (p<0.01). At 15 weeks, Ang II was infused at 1000 ng/kg/h 
for 4 weeks to evaluate its effect on pressor response. The infusion elicited a spike in 
MAPs of both control and db/db mice compared to the previous week (p<0.01). After the 
initial increase, MAP of control mice regressed towards baseline. However, MAP of 
db/db mice remained elevated throughout the infusion period (p<0.05). This is the first 
report to demonstrate increases in AT1R expression in db/db mice. The prolonged 
pressor response to Ang II by db/db mice could, in part, be attributed to the upregulation 
of AT1R and preexisting elevation in plasma Ang II. 
Poster accepted in the 63rd High Blood Pressure Research Conference, Chicago 2009 
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